Marker Therapeutics, Inc. (MRKR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRKR Stock Price Chart Interactive Chart >
MRKR Price/Volume Stats
| Current price | $0.34 | 52-week high | $3.65 |
| Prev. close | $0.34 | 52-week low | $0.28 |
| Day low | $0.32 | Volume | 95,300 |
| Day high | $0.35 | Avg. volume | 582,243 |
| 50-day MA | $0.38 | Dividend yield | N/A |
| 200-day MA | $1.01 | Market Cap | 28.23M |
Marker Therapeutics, Inc. (MRKR) Company Bio
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Latest MRKR News From Around the Web
Below are the latest news stories about Marker Therapeutics Inc that investors may wish to consider to help them evaluate MRKR as an investment opportunity.
Why Are Marker Therapeutics Shares Trading Lower On Thursday?Marker Therapeutics Inc (NASDAQ: MRKR ) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1 . The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting. No dose-limiting toxicities, cytokine release syndrome, or neurotoxicity were observed. 1 MRD+ patient became MRD- after infusion … Full story available on Benzinga.com |
Marker Therapeutics Announces Clinical Program Updates and Pipeline ExpansionResults from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trial |
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company’s clinical programs, manufacturing processes and pipeline. The webcas |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
MRKR Price Returns
| 1-mo | -2.86% |
| 3-mo | -8.50% |
| 6-mo | N/A |
| 1-year | -87.41% |
| 3-year | -94.18% |
| 5-year | -90.91% |
| YTD | -64.22% |
| 2021 | -34.47% |
| 2020 | -49.65% |
| 2019 | -48.11% |
| 2018 | 41.58% |
| 2017 | 1.03% |
Loading social stream, please wait...